Clicky

Xenon Pharmaceuticals Inc.(XENE) News

Date Title
Apr 4 Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 19 Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Mar 12 Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
Mar 9 Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
Mar 5 Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
Jan 8 Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
Jan 3 Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 4 Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Dec 4 After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain
Dec 2 Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
Nov 30 Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
Nov 29 Xenon Pharmaceuticals Announces Proposed Public Offering
Nov 28 Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
Nov 27 The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
Nov 27 UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study
Nov 27 Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
Nov 27 Xenon drug misses main goal of depression study
Nov 9 Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript
Nov 9 Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
Nov 8 Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update